AXSM Axsome Therapeutics (AXSM) Q1 FY26 earnings call
Axsome Therapeutics delivered strong Q1 FY26 results, driven by robust commercial performance of AUVELITY and SUNOSI, and a significant FDA approval for AUVELITY in Alzheimer's disease agitation. This approval led to a substantial increase in the product's peak sales outlook and prompted sales force expansion. The company continues to advance a broad, late-stage neuroscience pipeline, with several key regulatory submissions and clinical trial initiations planned, positioning it for sustained long-term growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
AXSM operating KPIs by quarter
| KPI | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| New prescribers activated AUVELITY | 5,500+Additionally, more than 5,500 new prescribers were activated in the quarter, bringing the total number of unique prescribers for AUVELITY since launch to approximately 60,000.Source: earnings call transcript | 6,800+In addition to accelerated new patient starts, the expanded sales force activated more than 6,800 new Auvelity prescribers in the quarter, representing 21% growth versus the previous quarter, bringing the total number of unique prescribers since launch to approximately 69,000.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.